Tofacitinib for immune-related myocarditis not responding to steroids
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether tofacitinib, a pill that calms the immune system, can help people whose heart inflammation caused by cancer immunotherapy (called ICI) is not improving with steroid treatment. It may offer a new option for those with this rare but serious side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have had cancer treatment with immunotherapy drugs (like PD-1, PD-L1, or CTLA-4 inhibitors), for any type of cancer.
- You have been diagnosed with myocarditis (inflammation of the heart muscle) that is related to your immunotherapy, according to current guidelines.
- Your heart inflammation has not responded to at least 2 days of steroid treatment (prednisone or equivalent).
- You agree to stop your immunotherapy treatment during the study.
- You must not have an untreated or uncontrolled infection, and if you are able to become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
This trial tests whether the drug tofacitinib can help people with ALS by calming an overactive immune system. You’ll need a genetic test to see if your immune profile matches what the study is looking for.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This trial studies the use of a medication called tofacitinib in children and teenagers with juvenile idiopathic arthritis (JIA), a type of arthritis that starts in childhood. The goal is to see if the drug helps reduce joint pain and inflammation.
This study tests whether combining two medicines, iguratimod and tofacitinib, works better than taking either alone for people with rheumatoid arthritis whose symptoms are not well controlled by their current treatment. If you join, you might get both drugs together to see if it helps reduce pain and swelling.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hear when a new Glucocorticoid Resistant ICIs-related Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.